Attention: This is the dev site

Log In

Forgot Password?
Create New Account

Loading... please wait

Want step therapy reform? Please step forward!

May 22, 2023

Latest Advocacy News

  • On May 3, the Drug Enforcement Administration (DEA) announced a temporary extension of COVID-19 telemedicine flexibilities for prescribing of controlled substances. This is a significant win for AAN advocacy and will promote patient access to care via telemedicine following the May 11 termination of the Public Health Emergency and will allow for further consideration of feedback from stakeholders on a permanent solution.
  • The AAN had previously submitted comments on March 22 in response to a proposed rule from the DEA impacting prescribing of controlled substances via telemedicine following the termination of the public health emergency. The AAN’s comments primarily addressed alignment with other telehealth flexibilities and ways in which the proposed rule could be implemented to minimize burden on providers.

Issue in Focus

On May 11, the Senate Committee on Health, Education, Labor, and Pensions held a hearing to consider several pieces of health care legislation, including the S. 1339 Pharmacy Benefit Manager Reform Act. In response to advocacy from the AAN and our partner organizations, a bill to reform step therapy requirements, S. 652 Safe Step Act, was introduced as an amendment to S. 1339 by Sen. Lisa Murkowski (R-AK) and passed out of committee with near unanimous support.

Step therapy, or fail first, requirements are a utilization management tool that requires patients to use lower-cost medications before being able to access the drug that was prescribed. The Safe Step Act would ensure that employer health plans and pharmacy benefit managers provide expedient and medically reasonable step therapy exceptions process―allowing patients to access the care they need in a timely manner.

The AAN signed a letter of support for the inclusion of this legislation which was sent to committee members in advance of the hearing. We will continue to advocate for full passage of this bill in the Senate and the House this Congress. To help us with our advocacy efforts, we urge members to share their stories of dealing with step therapy requirements using our Action Center.

 

What We're Reading

  • US Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute (Reuters)
  • Biden nominates Monica Bertagnolli to head NIH (STAT)
  • Appeals court temporarily pauses Texas ruling that overturned ObamaCare requirement (The Hill)
  • How a green card freeze will exacerbate the nursing crisis (Politico)